Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Last updated: February 11, 2025
Sponsor: Alnylam Pharmaceuticals
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neuropathy

Nerve Injury

Amyloidosis

Treatment

N/A

Clinical Study ID

NCT05040373
ALN-TTR02-010
  • Female

Study Summary

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Documentation that the patient was exposed to patisiran-LNP at any point startingfrom 12 weeks before LMP or at any point during pregnancy

Exclusion

Exclusion Criteria:

  • There are no exclusion criteria for participation in this program.

Study Design

Total Participants: 10
Study Start date:
August 01, 2020
Estimated Completion Date:
October 12, 2030

Connect with a study center

  • Clinical Trial Site

    Nantes,
    France

    Active - Recruiting

  • Clinical Trial Site

    Münster,
    Germany

    Active - Recruiting

  • Clinical Trial Site

    Pavia,
    Italy

    Active - Recruiting

  • Clinical Trial Site

    Groningen,
    Netherlands

    Active - Recruiting

  • Clinical Trial Site

    Lisboa,
    Portugal

    Active - Recruiting

  • Clinical Trial Site

    Madrid,
    Spain

    Active - Recruiting

  • Clinical Trial Site

    Iowa City, Iowa 52242
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.